

## Five-year summary

in € M, except share data	2017	2016	2015	2014	2013
<b>Statements of income</b>					
Revenue	17,784	16,570	15,455	12,145	11,215
Earnings before interest, taxes, depreciation and amortization (EBITDA)	3,098	3,110	2,777	2,221	2,173
Operating income (EBIT)	2,362	2,409	2,129	1,693	1,683
Delivered EBIT <sup>1</sup>	2,088	2,133	1,873	1,532	1,574
Net income (attributable to shareholders of FMC AG & Co. KGaA)	1,280	1,144	955	781	811
Basic earnings per share in €	4.17	3.74	3.14	2.58	2.67
<b>Balance sheets</b>					
Current assets	6,374	6,884	6,172	5,291	4,323
Non-current assets <sup>2</sup>	17,651	18,620	17,074	15,382	12,196
Total assets <sup>2</sup>	24,025	25,504	23,246	20,673	16,519
Current liabilities <sup>3</sup>	5,300	5,299	4,139	3,027	2,713
Non-current liabilities <sup>2,3</sup>	7,897	9,154	9,301	9,258	6,815
Equity	10,828	11,051	9,806	8,388	6,991
Total liabilities and equity <sup>2</sup>	24,025	25,504	23,246	20,673	16,519
Total debt	7,448	8,132	7,943	7,799	6,063
<b>Cash Flow</b>					
Net cash provided by (used in) operating activities	2,192	1,932	1,767	1,355	1,532
Free cash flow (net cash provided by (used in) operating activities after capital expenditures, before acquisitions and investments)	1,351	1,017	924	662	984
<b>Share data</b>					
Year-end ordinary share price Frankfurt, XETRA in €	87.78	80.45	77.73	61.85	51.73
Year-end ordinary share price (ADS) New York in \$	52.55	42.21	41.84	37.14	35.58
Weighted average number of shares	306,563,400	305,748,381	304,440,184	302,339,124	303,815,122
Total dividend amount <sup>4</sup>	325	294	244	237	232
Dividend per share <sup>4</sup> in €	1.06	0.96	0.80	0.78	0.77
<b>Employees</b>					
Full-time equivalents	114,000	109,319	104,033	99,895	90,690
<b>Operational ratios in %</b>					
Operating income margin	13.3	14.5	13.8	13.9	15.0
Basic earnings per share growth	11.6	19.3	21.4	-3.2	-12.0
Organic revenue growth	6.6	7.0	6.5	5.3	4.6
Return on invested capital (ROIC) <sup>2</sup>	8.6	7.8	7.1	6.9	7.8
Net debt/EBITDA ratio <sup>5</sup>	2.1	2.3	2.6	3.1	2.5
Net cash provided by (used in) operating activities in % of revenue	12.3	11.7	11.4	11.2	13.7
Free cash flow in % of revenue	7.6	6.1	6.0	5.5	8.8
Equity ratio (equity/total assets) <sup>2</sup>	45.1	43.3	42.2	40.6	42.3
<b>Dialysis care data</b>					
Treatments in M	48.3	46.5	44.6	42.7	40.5
Patients	320,960	308,471	294,381	286,312	270,122
Dialysis clinics	3,752	3,624	3,418	3,361	3,250

<sup>1</sup> Operating income less noncontrolling interests.

<sup>2</sup> As a result of deferred tax netting, non-current assets and liabilities were adjusted to conform the current year's presentation (2015: €154 M, 2014: €174 M, 2013: €185 M).

<sup>3</sup> Debt issuance costs were reclassified from current liabilities to conform to the current year's presentation (2014 and 2013 €5 M each year).

<sup>4</sup> 2017: Proposal to be approved by the Annual General Meeting on May 17, 2018.

<sup>5</sup> EBITDA is adjusted for non-cash charges (2017: €51M; 2016: €65 M; 2015: €48 M; 2014: €32 M; 2013: €35 M).